Prediction of inhibitors in hemophilia

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 12, 2008, Pages 2045-2047

  White, Gilbert C ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; GENETIC ASSOCIATION; HEMOPHILIA; HEREDITY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MISSENSE MUTATION; NOTE; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AUTOANTIBODIES; GENETIC PREDISPOSITION TO DISEASE; HEMOPHILIA A; HISTOCOMPATIBILITY TESTING; HUMANS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 56749132018     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03205.x     Document Type: Note

References (13)

1. Shapiro SS, Holburn RR. Pathophysiology of anticoagulants in hemophilia A and B. In: Brinkhous KM, ed. Hemophilia and New Hemorrhagic Diseases. Chapel Hill: University of North Carolina Press, 1970:141-51.
2. Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immunol Immunopathol 1977; 8: 34-8.
3. White GC II, McMillan CW, Blatt PM, Roberts HR. Factor VIII inhibitors: a clinical overview. Am J Hematol 1982; 13: 335-42.
4. Astermark J, Berntorp E, White GC II, Kroner BL. The Malmö International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
5. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
6. Tuddenham EG, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-5.
7. Oldenburg J, Schroder J, Brackmann HH, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-8.
8. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 6): 15-22.
9. ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, van den Berg HM, van der Bom JG, on behalf of the CANAL Study Group. Risk stratification for inhibitor development at first treatment for severe hemophilia A: A tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
10. White GC II, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost 2005; 3: 1676-81.
11. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta, IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
12. Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
13. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.